From Significance of the study to Public health relevance:
Given that: (1) cancer suppressor p53 is mutated in more than 50% of human cancers of different tissue origin; (2) p53 pathway is altered in about 80% of tumors.; (3) our understanding is incomplete in terms of molecular targets and the oncogenic/malignant pathways involved in mutant p53-overexpressing tumors; (4) cancer causes the highest economic loss compared to all the known causes of death worldwide; and (5) cancer causes the considerable economic loss worldwide, there is an urgent need to find: (i) a cheaper alternative to the existing expensive drugs; (ii) a side-effect-free natural product-based drug; and (iii) a way to effectively treat and stall metastatic progression and relapse of mutant p53-overexpressing human cancers.
From therapeutic strategy to Research Findings:
(i) Therapeutic strategy:
This study suggests a therapeutic strategy for stalling the progression of p53-deficient/deleted or mutant-p53 expressing metastatic cancers. By activating tumor suppressor p53’s unmutated “homologous protein such as TAp73/p63” in p53-deficient or mutant-p53 expressing metastatic cancer cells, one can stall their progression.
(ii) Research findings:
This study suggests that Tramadol (brand name: Ultram) may function as a tumor suppressor gene in mutant p53 expressing human cancers.
This study suggests that Tramadol (brand name: Ultram), by increasing the expression of its target gene, it may increase the expression of tumor/metastasis suppressors genes, such as BTG2, TIMP3, p53, TA-p73, p53, and others. Thereby, it may inhibit the migration and invasion of metastatic cancer cells expressing mutant-p53 (figure1).
Given the ability of Tramadol (brand name: Ultram) to induce the expression of a number of tumor/metastasis suppressor genes, it may be used, either alone or in combination with other anticancer drugs, to inhibit the progression of p53-mutated invasive metastatic tumors. Taken together, this study suggests, for the first time, that oncologists may consider treating metastatic cancer patients with activators of Act1 (Adaptor for IL-17 receptors), as it may stall the progression of advanced metastatic cancers. (figure 2).
Details of the research findings:
Idea Proposed/Formulated by Dr. L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
Undisclosed mechanistic information: How Tramadol increases the expression of tumor suppressor genes, such as CCM3/KRIT1, TPM1, p53, TAp63, TAp73, and others, in mutant p53 expressing cancer cells?
For purchase and payment details, you may reach us at firstname.lastname@example.org
Citation: Boominathan, L., Analgesics awake the sleeping/cancer-protecting angels in mutant p53-expressing human tumors: Tramadol (brand name: Ultram), an analgesic, increases the expression of tumor suppressors genes, such as CCM3/KRIT1, TPM1, p53, TAp63, TAp73, INK4a/ARF, and others, and induces regression of p53-mutated human tumors, via down-regulation of its target gene, 13/October/2018, 10.49 am, Genome-2-Biomedicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com